PAION AG / Key word(s): Research Update 05.11.2014 06:26 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- PAION'S PARTNER ONO DECIDES NOT TO FILE FOR REGULATORY APPROVAL OF REMIMAZOLAM IN JAPAN AND WILL RETURN ITS REMIMAZOLAM RIGHTS FOR JAPAN TO PAION - Ono has decided to discontinue the project on strategic reasons considering issues in pharmacokinetic features, while no adverse events of concern were observed during clinical trials - Ono will return its license for Japan and initiate the process of data and Know how transfer to PAION - Remimazolam is now available for licensing in Japan - PAION is exploring an alternative filing strategy in Japan Aachen (Germany), 05 November 2014 - PAION AG a Specialty Pharma Company (ISIN DE000A0B65S3; Frankfurt Stock Exchange General Standard: PA8) today announced that its Japanese development partner, Ono Pharmaceutical Co., Ltd. ("Ono"), has informed PAION AG that they have decided today "to discontinue the project on strategic reasons considering issues in pharmacokinetic features, while no adverse events of concern were observed during clinical trials". Ono successfully completed the Remimazolam development program in anaesthesia - the lead indication in Japan - in November 2013. The primary efficacy endpoint of effectiveness as a general anaesthetic was achieved by 100% of patients with no adverse events of concern and a clinically meaningfully less cardio depressive effect as compared to Propofol. After that the remaining development for a filing in Japan was finished including further studies to elucidate the pharmacokinetic findings seen in another development program ICU sedation, which supported PAIONs view that the data package can be filed for general anaesthesia. Ono now has decided to stop its development activities and to return the license. There will be no repayment for received milestone payments. Remimazolam is now available for licensing in Japan to other parties. PAION is evaluating an alternative filing strategy for Remimazolam in Japan in the indication general anaesthesia through PAION or another partner. PAION has full access to all data generated by Ono. The parties will closely work together in order to make the transition as fast as possible. PAION expects no impact on its ongoing development programs in General Anaesthesia in Europe and Procedural Sedation in the US. Ono entered into a license agreement with PAION UK LIMITED (formerly CeNeS Limited) in 2007, acquiring the exclusive right to develop and market Remimazolam in Japan. ### Contact Ralf Penner Director Investor Relations / Public Relations PAION AG Martinstrasse 10-12 52062 Aachen - Germany Phone: +49 241 4453-152 E-mail: r.penner@paion.com www.paion.com Disclaimer: This release contains certain forward-looking statements concerning the future business of PAION AG. These forward-looking statements contained herein are based on the current expectations, estimates and projections of PAION AG's management as of the date of this release. They are subject to a number of assumptions and involve known and unknown risks, uncertainties and other factors. Should actual conditions differ from the Company's assumptions, actual results and actions may differ materially from any future results and developments expressed or implied by such forward-looking statements. Considering the risks, uncertainties and other factors involved, recipients should not rely unreasonably upon these forward-looking statements. PAION AG has no obligation to periodically update any such forward-looking statements to reflect future events or developments. 05.11.2014 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: PAION AG Martinstr. 10-12 52062 Aachen Germany Phone: +49 (0)241-4453-0 Fax: +49 (0)241-4453-100 E-mail: info@paion.com Internet: www.paion.com ISIN: DE000A0B65S3 WKN: A0B65S Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------
DGAP-Adhoc: PAION'S PARTNER ONO DECIDES NOT TO FILE FOR
Top 10 Most Recent News Articles
Thanksgiving Dog Safety Is a Pet Care Reality Check
A crowded Thanksgiving kitchen can turn a well-behaved dog into a scavenger with lousy odds. Camp Bow Wow’s holiday guidance is not pretending the meal itself is the problem; the trouble is that a house full of distracted people, rich food and unsecured trash creates a pile of easy mistakes. For pet owners, that is a fair reminder. For anybody watching the pet-care...
Continue Reading
Peptide Labels Cannot Substitute for Clinical Care
A Label Is Not a Care Plan Those three little words, research use only, carry far more weight than a flashy product page would have people believe. The HelloNation article featuring wellness expert Andres Giraldo makes a plain but necessary distinction: a research-use-only, or RUO, label does not turn a peptide into prescribed treatment, and it sure does not establish...
Continue Reading
Washington-to-Asia Advisory Deal Targets Policy Risk
Policy bottlenecks are becoming a cost center across Southeast Asia. That is the plain-English backdrop for the strategic partnership announced November 18, 2026, by Beacon Global Strategies and Vriens & Partners. Neither firm is selling a factory, a chip design, or a new energy project. They are selling something companies increasingly cannot afford to improvise: a...
Continue Reading
Spruce Spins Adrenyx En Route to Nasdaq in 2027
New Frontiers: Adrenyx Biosciences Takes Shape Well, here's a new chapter in biotech drama. Spruce Biosciences, a name you might have tangled with if you're into tickers like NASDAQ:SPRB, just carved out a niche with the birth of Adrenyx Biosciences. The play? A separate company eyeing the endocrinology space, setting its sights on tackling congenital adrenal hyperplasia...
Continue Reading
Tactical Tomahawk Motor Deal Puts Propulsion in Focus
A missile program lives or dies on unglamorous hardware, and solid rocket motors are about as unglamorous as it gets until somebody cannot build enough of them. Raytheon has awarded Ursa Major and Avio USA a joint contract to develop solid rocket motors for the U.S. Navy’s Tactical Tomahawk missile program. That is the whole headline, and it matters more than the thin...
Continue Reading
Insider Risk Makes Human Judgment a Security Priority
A badge, a password, and a locked gate can all look reassuring right up until the person holding them starts to crack. Signpost Six's new report, The Psychology of Insider Risk, lands on an uncomfortable truth: the most consequential security weakness may not be a system at all. It may be an employee under strain, in conflict, in debt, making a mistake, or being quietly...
Continue Reading
Google Search Data Sharing Faces a Privacy Reality Check
Search queries are messy little confessions, and that is exactly why this case deserves more than a bureaucratic shrug. Woodway Assurance's independent assessment says Google's search-query data could be treated as anonymized for sharing under the Digital Markets Act, but only if the European Commission tightens parts of its July 2026 framework. That is not a clean bill...
Continue Reading
Kawneer’s OptiQ Window Wins a Useful Design Signal
Three Nods, One Very Practical Product Claim Windows rarely stir much excitement outside an architect’s specification binder, but Kawneer has put together a respectable run with its OptiQ Offset Fixed/Projected Series Window. On November 18, 2026, the architectural aluminum-systems maker said the product had won in the Windows and Doors category at both the 2026...
Continue Reading
A Decade of Giving: Light the World Initiative's Impact
The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...
Continue Reading
Anycubic Pushes Toward a Smoother 3D Printing Ecosystem
Friction Is the Enemy in Consumer 3D Printing A printer that makes a beautiful object only after three failed attempts is not a consumer product; it is a weekend argument with plastic. That is the useful lens for Anycubic's Formnext 2026 showing in Frankfurt on November 18. The company is not merely rolling out FDM and resin machines at Booth F01 in Hall 12.0. It is...
Continue ReadingTop 5 Most Recently Viewed Articles
Bioretec's Innovative Annual Report Showcases New Progress
Bioretec Ltd's Annual Report Overview Bioretec Ltd has recently published its annual report for 2024, offering insights into the company's growth and achievements over the past year. This report showcases the advancements made in biodegradable orthopedic implants, positioning the company at the forefront of innovative healthcare solutions. Company Highlights Bioretec...
Continue Reading
Market Overview: Asia Stocks See Fluctuations Amid Election Fears
Market Dynamics in Asia: A Closer Look In recent trading sessions, Asian stocks demonstrated muted movements in response to an absence of compelling trading signals, while Japanese shares experienced a notable decline driven by impending democratic choices. Investors are particularly focused on the Japanese electoral scene, which is expected to significantly influence...
Continue Reading
TScan Therapeutics Secures $52.5 Million Loan to Support Growth
TScan Therapeutics Secures $52.5 Million Loan from Silicon Valley Bank WALTHAM, Mass. — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company dedicated to developing innovative therapies for cancer treatment, has announced an exciting milestone. The company has entered into a term loan facility with Silicon Valley Bank (SVB) that offers up to...
Continue Reading
Celebrating Four Years of SpaceX's Starlink Internet Service
Four Years of Starlink Connectivity Four years ago, SpaceX, under the visionary leadership of Elon Musk, began its journey in satellite internet services by activating Starlink for its first paying customer. This significant milestone was established on a date that marks the beginning of a transformative era for internet connectivity. Impact of Starlink on Global Internet...
Continue Reading
AllenComm Receives Esteemed Recognition in eLearning Field
AllenComm Earns Top Honor for eLearning Localization AllenComm, a prominent player in the realm of innovative learning experiences, has recently been recognized as one of the Top Content Providers for eLearning Localization by a well-regarded industry source. This accolade reflects the company's dedication to delivering high-quality, effective educational solutions that...
Continue Reading